Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759564 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00759564 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT00759564, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).
Interventions
- DRUG CP-70,429 and PF-03709270
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759564
The ClinicalTrials.gov registry entry for NCT00759564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-70,429 and PF-03709270 is the first listed.
NCT00759564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759564 about?
NCT00759564 is a clinical study titled "A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function". This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).
What is the current status of trial NCT00759564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00759564?
The interventions under investigation include: CP-70,429 and PF-03709270 (DRUG).
Who is sponsoring clinical trial NCT00759564?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.